Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)

Brandes J.; Kudrow D.; Klise S.; Krege J. H.; Case M. G.; Raskin J.; Khanna R.; Vasudeva R.

首页> 外文期刊>Headache >Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)

【24h】

Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)

机译：Lasmiditan的长期安全性和疗效在一年期间偏头痛的急性治疗：开放标签第3期研究（角斗士）的中期结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Headache》 |2019年第1期|共1页
作者
Brandes J.; Kudrow D.; Klise S.; Krege J. H.; Case M. G.; Raskin J.; Khanna R.; Vasudeva R.;
展开▼
作者单位

Eli Lilly &

Co Missoula MT USA;

Eli Lilly &

Co Windlesham Surrey England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类诊断学;
关键词

相似文献

外文文献
中文文献

1. Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR) [J] . Brandes J., Kudrow D., Klise S., Headache . 2019,第Suppla1期

机译：Lasmiditan的长期安全性和疗效在一年期间偏头痛的急性治疗：开放标签第3期研究（角斗士）的中期结果
2. Long-Term, Open-Label Safety Study of Rimegepant 75 mg for the Treatment of Migraine (Study 201): Interim Analysis of Safety and Exploratory Efficacy [J] . Lipton R. B., Berman G., Kudrow D., Headache . 2019,第Suppla1期

机译：长期，开放式标签安全性研究，对偏头痛的治疗75 Mg（研究201）：安全性和探索性疗效的临时分析
3. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN) [J] . Li Shen Loo, Brian M. Plato, Ira M. Turner, BMC Neurology . 2019,第1期

机译：抢救或复发剂量的Lamiditan对偏头痛急性治疗的疗效和安全性的影响：三期试验（SAMURAI和SPARTAN）的发现
4. SAFETY AND USABILITY FACTORS IN DEVELOPMENT OF A NOVEL, AUTOMATED TREATMENT DEVICE FOR ACUTE MIGRAINE [C] . David M. George, Guido Pagnacco, Kevin E. Willey, Annual rocky mountain bioengineering symposium;International ISA biomedical sciences instrumentation symposium . 2017

机译：开发新型自动治疗急性偏头痛的安全性和可用性因素
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Interim results of a prospective randomized open-label Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study) [O] . Jan Lewis Brandes, Suzanne Klise, John H Krege, -1

机译：Lamiditan长期治疗偏头痛的长期安全性和有效性的前瞻性随机开放标签第3期研究的中期结果（GLADIATOR研究）
7. Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study [O] . Jan Lewis Brandes, Suzanne Klise, John H Krege, 2020

机译：Lasmiditan对偏头痛急性治疗的长期安全性和疗效：角斗士研究的最终结果

Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)

著录项

相似文献

相关主题

期刊订阅